Phase 3 N=76 ARREST PAD (Peripheral Arterial Disease)
Arterial Occlusive Disease · Intermittent Claudication · Insulin Resistance
Primary: Lower Extremity Skeletal Muscle Glucose Uptake — 62.9; 48.6; 49.5 umol/kg/min
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=604 Diagnostic Tools to Establish the Presence and Severity of Peripheral Arterial Disease in People With Diabetes
Diabetic Foot · Peripheral Arterial Disease · Diabetic Foot Ulcer
Primary: Diagnostic Accuracy — 36; 42; 55; 41 percentage
N/A N=10 Improving Walking in Peripheral Artery Disease
Peripheral Artery Disease
Primary: Changes in Walking Distance After Three-months Intervention — 289.68; 262.95 meters
N/A N=85 Comprehensive Magnetic Resonance of Peripheral Arterial Disease
Peripheral Artery Disease
Primary: Plaque Volume — 10.5; 10.5; 10.8 cm^3 — p=0.32
Phase 4 N=840 Alprostadil in Peripheral Arterial Occlusive Disease (PAOD) Stage IV
Peripheral Arterial Occlusive Disease
Primary: Complete Healing of Ischemic Necroses and Ulcerations at 12 Weeks After the End of Study Drug Treatment — 49; 43; 27; 30 participants — p=0.2587
Phase 4 N=102 Effectiveness of Intensive Lipid Modification Medication in Preventing the Progression of Peripheral Arterial Disease (The ELIMIT Study)
Peripheral Arterial Disease
Primary: Effect of Intensive Lipid Modification Medication Therapy on Progression of Atherosclerosis and Restenosis of Femoral Arteries Measured Using High Resolution Magnetic…
N/A N=14 Impacts of Mitochondrial-targeted Antioxidant on Peripheral Artery Disease Patients
Peripheral Arterial Disease · Peripheral Artery Disease
Primary: Endothelial Function — 6.13; 3.78 % dilation
N/A N=238 Digital Ankle Brachial Index (ABI) as a Screening Tool in Detecting Peripheral Arterial Disease
Peripheral Artery Disease · Amputation · Smoking
Primary: Positive Predictive Value of Digital ABI in Diagnosing PAD — 8; 2 Participants
N/A N=305 TEsting for Arterial Disease in Diabetes (TrEAD) Study
Diabetic Foot · Peripheral Arterial Disease · Diabetic Foot Ulcer
Primary: Diagnostic Accuracy — 95; 77; 60; 86 Percent
Phase 3 N=110 Effects of Dietary Flaxseed on Symptoms of Cardiovascular Disease in Patients With Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Number of Participants With All-cause Mortality, Cardiovascular Mortality, Stroke, and Myocardial Infarctions — 4; 5 participants
N/A N=347 Community-Based Detection and Treatment of Peripheral Arterial Disease in Hispanics.
Peripheral Arterial Disease
Primary: Effect of an Exercise Intervention on Walking Ability (Functional Outcome) — 301.4; 185.1 meters
Phase 2 N=119 Magnetic Resonance Angiography for Peripheral Arterial Disease (PAD)
Peripheral Arterial Disease (PAD)
Primary: Segment-level Sensitivity and Specificity of VE-MRI at 3 Ferumoxytol Dosing Levels and Differences in Sensitivity and Specificity by Dose Group — 71.8; 76.8; 81.8; 71.2…
Phase 2 N=159 Granulocyte-Macrophage Stimulating Factor in the Treatment of Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Change in Peak Walking Time During Treadmill Exercise Tolerance Test From Baseline to 3 Months — 109; 56 seconds
Phase 4 N=186 Efficacy Evaluation of Dotarem Compared to Gadovist in the Diagnosis of Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Intra-patient Accuracy (Percent Agreement), On-site Data — 77.1; 80.6 percentage of agreement
Phase 2 N=10 Rilonacept to Improve Artery Function in Patients With Atherosclerosis
Coronary Artery Disease · Atherosclerosis · Inflammation
Primary: C-Reactive Protein (CRP) — 3.7; 4.6 mg/L
N/A N=121 Revolution™ Peripheral Atherectomy System for Lower Extremity Peripheral Arterial Revascularization
Peripheral Artery Disease
Primary: Safety Endpoint: Number of Participants With Freedom From Major Adverse Events — 110 Participants
N/A N=35 Exercise Rehabilitation in Veterans With PAD
Peripheral Arterial Disease · Intermittent Claudication
Primary: Modified Physical Performance Test — 31.8; 32.3 scores on a scale
N/A N=12 Feasibility Study to Evaluate Therapeutic Ultrasound (TUS) to Acutely Increase the Perfusion in Peripheral Arterial Disease (PAD)
Peripheral Arterial Disease
Primary: Mean Acute Flow Rate Difference During TUS Treatment Sessions — 27.3 Percent change (%)
N/A N=20 Robotic-Assisted Peripheral Intervention for Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Device Technical Success — 29 lesions
N/A N=112 Evaluation of the FreedomFlow™ Orbital Atherectomy System to Treat Peripheral Artery Disease
Peripheral Arterial Disease
Primary: Technical Success — 144 lesion
Phase 4 N=60 Liraglutide and Peripheral Artery Disease
Type 2 Diabetes · Peripheral Arterial Disease
Primary: Peripheral Transcutaneous Oxygen Pressure — 54.2; 43.4 mmHg — p=<0.001
N/A N=21 Dietary Nitrates and Vascular Function in Patients With Peripheral Artery Disease
Peripheral Artery Disease
Primary: Change in Vasodilator Capacity — 16.2; 16.4; 16.5; 14.2 ml/100ml tissue/min
N/A N=1,455 Prevention of Ischemic Events in Patients With Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Incidence of Major Cardiovascular Events — 112; 47; 51; 17 participants — p=<0.001
N/A N=983 Safety Assessment of Angioplasty Procedures
Angiospastic; Disorder
Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants
Phase 4 N=20 DOTAREM®-Enhanced MRA Compared to GADOVIST®-Enhanced MRA in Patients With Abdominal or Lower Limb Arterial Diseases
Peripheral Arterial Disease
Primary: Overall Image Quality of MRA Images — 56; 48 Images
N/A N=19 Impedance Sensor Evaluated in Peripheral Artery Disease for Tissue Detection
Peripheral Vascular Disease
Primary: The Ability of Clotild® Smart Guidewire System (CSGS) to Acquire Electrophysiological Measurements in the Lesion and/or Subintimal. — 17 Participants
N/A N=187 Clinical Evaluation of the BlueDop Vascular Expert for Assessing Peripheral Arterial Disease
Peripheral Arterial Disease
Primary: Determination of Presence or Absence of Significant PAD With BVE and Arterial Duplex — 62; 14; 212; 43 Limbs
N/A N=797 Patient-centered Outcomes Related to TReatment Practices in Peripheral Arterial Disease: Investigating Trajectories (PORTRAIT)
Peripheral Arterial Disease · Quality of Life · Quality of Care
Primary: Peripheral Artery Disease (PAD) - Specific Health Status — 70.7; 66.9 units on a scale of 0-100
N/A N=125 Non-invasive Computer-Aided Phenotyping of Vasculopathy
Carotid Atherosclerosis · Peripheral Arterial Disease
Primary: Measurement Bias of Calcification Analyzed by vascuCAP™ Non-invasively Relative to Histopathology as Ground Truth. — -0.47; .07 mm2
Phase 3 N=366 Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Participants With Peripheral Arterial Occlusive Disease Fontaine Stage IIB
Peripheral Arterial Diseases
Primary: Percent Change From Baseline in Initial Claudication Distance (ICD) at Week 12 — 21.99; 51.17 percent change — p=0.0041